EP2830546A1 - Variable zone high metal to vessel ratio stent and method - Google Patents
Variable zone high metal to vessel ratio stent and methodInfo
- Publication number
- EP2830546A1 EP2830546A1 EP13708291.3A EP13708291A EP2830546A1 EP 2830546 A1 EP2830546 A1 EP 2830546A1 EP 13708291 A EP13708291 A EP 13708291A EP 2830546 A1 EP2830546 A1 EP 2830546A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- vessel
- zone
- metal
- high metal
- vessel ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002184 metal Substances 0.000 title claims abstract description 333
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 333
- 238000000034 method Methods 0.000 title claims description 20
- 206010002329 Aneurysm Diseases 0.000 claims abstract description 29
- 239000000463 material Substances 0.000 claims description 23
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 claims description 13
- 238000012384 transportation and delivery Methods 0.000 claims description 13
- 208000034423 Delivery Diseases 0.000 claims description 11
- 239000003102 growth factor Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 4
- 238000004381 surface treatment Methods 0.000 claims description 4
- 241000270295 Serpentes Species 0.000 claims description 2
- 210000000709 aorta Anatomy 0.000 claims description 2
- 230000002844 continuous effect Effects 0.000 claims 1
- 238000007788 roughening Methods 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 abstract description 11
- 238000007789 sealing Methods 0.000 abstract description 9
- 244000198134 Agave sisalana Species 0.000 description 7
- 235000011624 Agave sisalana Nutrition 0.000 description 7
- 210000001367 artery Anatomy 0.000 description 6
- 230000000975 bioactive effect Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 210000002254 renal artery Anatomy 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- -1 i .e. Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 238000000623 plasma-assisted chemical vapour deposition Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000001750 Endoleak Diseases 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010061307 Neck deformity Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000010329 laser etching Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000001363 mesenteric artery superior Anatomy 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- KRTSDMXIXPKRQR-AATRIKPKSA-N monocrotophos Chemical compound CNC(=O)\C=C(/C)OP(=O)(OC)OC KRTSDMXIXPKRQR-AATRIKPKSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000001020 plasma etching Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000003270 subclavian artery Anatomy 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2002/061—Blood vessels provided with means for allowing access to secondary lumens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2002/065—Y-shaped blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/848—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
- A61F2002/8486—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs provided on at least one of the ends
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91508—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other the meander having a difference in amplitude along the band
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91516—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other the meander having a change in frequency along the band
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91525—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other within the whole structure different bands showing different meander characteristics, e.g. frequency or amplitude
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0004—Rounded shapes, e.g. with rounded corners
- A61F2230/0013—Horseshoe-shaped, e.g. crescent-shaped, C-shaped, U-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0018—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in elasticity, stiffness or compressibility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0029—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in bending or flexure capacity
Definitions
- the present application relates to an Intra-vascular device aid method. More particularly, the present appl ication relates to a device for treatment of intra-vascu!ar diseases.
- ai n stent-grafts are we! I known for use in tubular shaped human vessels.
- Stent-grafts with custom side openi gs are someti mes fabricated to accommodate the particular vessel structure of each individual patient. Specifically, as the location of branch vessds emanati g from a main vessel , e.g., having the aneurysm, varies from patient to patient, stent-grafts are fabricated with side openi ngs custom! zed to match the posi ti on of the branch vessd s of the parti oil ar patient. However, custom fabrication of stent-grafts is rd ativdy expansive and time consuming.
- the stent-grafts must be depi oyed such that the custom si de openings are precisely al igned with the respective locations of the branch vessds. This is a rd ativdy complex procedure thus increasing the risk of the procedure.
- a vari abl e zone hi gh metal to vessd rati o stent i rid udes a proxi mai high metal to vessd ratio zone, a central low metal to vessd ratio zone, and a distal high metal to vessd ratio zone.
- the proxi mai high metal to vessel ratio zone is deployed with fixation and seal ing to healthy ti sue of a main vessel superior to branch vessd s and an aneurysm.
- the central low metal to vessd ratio zone is depl oyed di recti y on ostai of the branch vessd s.
- variable zone high metal to vessel ratio stent is integral , the variable zone high metal to vessel ratio stent is deployed in a single operation which reduces procedure time and complexity.
- FI G.1 is a perspective view of a variable zone high metal to vessel ratio stent in its final configuration in accordance with one embodiment
- FI G. 2 is a cross-sectional view of the vai able zone high metal to vessel ratio stent of FIG. 1 ;
- FI G.3 is a cross-sectional view of a vessel assembly incl uding a del ivery system incl uding the variable zone high metal to vessel ratio stent of FI GS. 1 and 2 in accordance with one embodiment;
- FI G. 4 is a cross-sectional view of the vessel assembly incl udi g the del ivery system at a late?" stage of deploying the variable zone high metal to vessel ratio stent of FIGS. 1 and 2 in accordance with one embodi mait;
- FI G. 5 is a cross-sectional view of the vessel assembly of FIGS.3 and 4 after dep! oyment of the vari abl e zone high metal to vessel rati o stent of FI GS. 1 and 2 in accordance with one embodiment;
- FI G. 6 is a cross-sectional view of the vessel assembly of FIG. 5 il l ustrating tissue ingrowth into the vari able zone high metal to vessel ratio s ent;
- FI G.7 is a cross-sectional view of a vessel assembly incl uding a vari able zone high metal to vessel ratio stent graft in accordance with another embodiment.
- FI G. 8 is a cross-sectional view of a vessel assembly incl uding a vari able zone high metal to vessel ratio stent graft in accordance with yet another embodiment.
- a variable zone high metal to vessel ratio stent 100 incl udes a proximal high metal to vessel ratio zone 118, a central low metal to vessel ratio zone 120, and a distal high metal to vessel ratio zone 122.
- FYoximal high metal to vessel rati o zone 118 is deployed with fixation and seal ing to healthy tissue of a main vessel 304 supeior to branch vessels 308, 310 and an aneurysm 308.
- variable zone high metal to vessel ratio stent 100 is integral , i .e., formed of a single piece and not a pl ural ity of separate pieces connected together, variable zone high metal to vessel ratio stent 100 is depl oyed in a singleopa-ation which reduces procedure time and complexity. This is in stark contrast to deploy! ng muiti pi e stents one withi n another to vary the metal to vessel ratio of the resulting muiti stent arrangement.
- FIG. 1 is a perspective view of a variable zone high metal to vessel ratio stent 100, e.g., an abdominal aortic stent, in its final configuration in accordance with one embodiment.
- FI G. 2 is a cross-sectional view of variable zone high metal to vessel ratio stent 100 of FIG. 1.
- Variable zone high metal to vessel ratio stent 100 is sometimes cal led an endol uminal flow disrupting device.
- Vari able zone high metal to vessel ratio stent 100 further incl udes a distal main opening 104 at a distal and 100D of vari able zone high metal to vessel ratio stent 100.
- the proxi mal end of a prosthesi s such as vari abl e zone high metal to vessel ratio stent 100 is the and closest to the heart via fhe path of blood flow whereas the distal end is the end furthest away from the heart during deployment.
- the distal end of the del i very system is usuai ly identified to the end that isfarthest from the operator (handle) while the proximal and of the del i very system i s the end nearest the operator (hand! e).
- thedis ai end of the del i very system i s the end that i s farthest f om the opa'ator (the end furthest from the handl e) whi I e the di stal end of the prosthesi s i s the end nearest the operator (the end nearest the handle), i .e., thedistai end of the del ivery system and the proxi mal end of the prosthesi s are the ends furthest from the hand! e whi I e the proximal end of the del i very system and thedistai end of the prosthesis are the ends nearest the handl e.
- those of ski ⁇ i n the art wi 11 understand that depending upon the access location, the prosthesi sand del ivery system description may be consistent or opposite in actual usage.
- Variablezone high metal to vessel ratio stent 100 is cyl indrical and includes a longitudinal axis L.
- a main lumen 108 isdefined by variable zone high metal to vessel ratio stent 100 and extends generally parallel to longitudinal axis L and between proximal mai opening 102 and distal mai opening 104 of variable zone high metal to vessel ratio stent 100.
- variable zone high metal to vessel ratio stent 100 has a substantially uniform diameter D.
- variable zone high metal to vessel ratio stent 100 has a non-uniform diameter.
- Variablezone high metal to vessel ratio stent IQO is a semi- permeabl e barri er made of patterned materi a! 108, e.g. , i s a I aser cut si ngl e tube or i s wire formed and welded.
- fluid e.g., blood
- variable zone high metal to vessel ratio stent 100 nourish, e.g., with oxygen and nutrients, the covered vessel wal I .
- hypoxia of the cova'ed vessel wal I is avoided.
- vari able zone high metal to vessel ratio stent 100 is permeable to tissue ingrowth.
- Longitudinal direction 112 is the direction along vari able zone high metal to vessel ratio stent 100 parallel to longitudinal axis L.
- Circumferential direction 114 is the direction along the circumference of variablezone high metal to vessel ratio stent 100 in plane perpendicular to longitudinal axis L of variable zone high metal to vessel ratio stent 100.
- Radial direction 118 is along a radius extending from longitudinal axis L in plane perpendicular to longitudinal axis L of vari able zone high metal to vessel ratio stent 100.
- Vari abl e zone high metal to vessel rati o stent 100 i nci udes vari abl e metal to vessel ratio zones 118, 120, 122.
- Vari able metal to vessel ratio zones 118, 120, 122 havedifferent metal to vessel ratios as defined below. Although three vari able metal to vessel ratio zones 118, 120, 122 are illustrated and discussed herein, in light of this disclosure, those of skill in the art will understand that vari able zone high metal to vessel ratio stent 100 includes more or I ess than three vari able metal to vessel ratio zones in other embodiments.
- Vari abl e metal to vessel rati o zones 118, 120, 122 are haei naf ter ref erred to as a proximal , e.g., first, high metal to vessel ratio zone 118, a central , e.g., second, low metal to vessel ratio zone 120, and a distal , e.g., third, high metal to vessel ratio zone 122, respectively.
- Proximal high metal to vessel ratio zone 118 is at proximal end 10OP of vari able zone high metal to vessel ratio stent 100.
- Distal high metal to vessel ratio zone 122 is at distal end 100D of vari able zone high metal to vessel ratio stent 100.
- Central low metal to vessel ratio zone 120 is between proximal high metal to vessel ratio zone 118 and distal high metal to vessel ratio zone 122.
- the metal to vessel ratio is defined as the area occupied by material 108 of proximal high metal to vessel ratio zone 118 for a unit area of proximal high metal to vessel ratio zone 118 when in the final configuration.
- Y is the metal to vessel ratio expressed as percent.
- the metal to vessel rati o can be expressed as a fraction, ag., 0.4 for this example, or as a percentage, e.g., 40% for this example. To convert, the fraction is multipl ied by 100 to obtain the percentage.
- the metal to vessel ratio of proximal high metal to vessel ratio zone 118 varies in the longitudinal direction 112 and/or in the circumferential direction 114 along variable zone high metal to vessel ratio stent 100.
- variable a i s def i ned when vari abi e zone high metal to vessel ratio stent 100 and thus proximal high metal to vessel ratio zone 118 is in the final configuration.
- Variablezone high metal to vessel ratio stent 100 is in the final configuration when in its final unconstrained expanded state, sometimes called at nominal deployment.
- variablezone high metal to vessel ratio stent 100 when the diameter of variablezone high metal to vessel ratio stent 100 is approximately equal , e.g., 10% to 20% oversized, to thediameter of the vessel in which variable zone high metal to vessel ratio stent 100 is bang deployed and variablezone high metal to vessel ratio stent 100 is at its natural unconstrai ed length at this diameter, vari able zone high metal to vessel ratio stent 100 is in its final state. Generally, once deployed within the vessel at its natural unconstrained length as discussed below, vari able zone high metal to vessel ratio stent 100 is in the final
- variablezone high metal to vessel ratio stent 100 is in a constrained configuration when variable zone high metal to vessel ratio stent 100 is constrained to a reduced diameter, e.g., within add ivery sheath. Further, variablezone high metal to essd ratio stent 100 is in a constrained configuration when variablezone high metal to vessel ratio stent 100 is constrained to a reduced or expanded length, e.g., by longitudinall compressing or expanding variablezone high metal to vessel ratio stent 100.
- holes 110 When in the constrained configuration, either in length, diameter, or both, holes 110 are collapsed resulting in a much higher metal to vessd ratio for vari able zone high metal to vessel ratio stent 100 than when variablezone high metal to vessel ratio stent 100 and is in its final configuration.
- the metal to vessd ratio of proximal high metal to vessel ratio zone 118 is sufficiently high to encourage tissue ingrowth around proximal high metal to vessd ratio zone 118.
- the metal to vessd ratio of proximal high metal to vessd ratio zone 118 is within the range of 30 percent to 80 percent (30-80%), more suitably within the range of 35 percent to 60 percent (35-60%). In one particular embodiment, the metal to vessel ratio is 40 percent (40%).
- Distal high metal to vessel ratio zone 122 also has a high metal to vessel ratio as defined above.
- distal high metal to vessel ratio zone 122 is identical in structure to proximal high metal to vessel ratio zone 118 and thus has the identical high metal to vessel ratio.
- the metal to vessel ratio of distal high metal to vessel ratio zone 122 is sufficiently high to encourage tissue ingrowth around distal high metal to vessel ratio zone 122 as wd I as to provide adequate aneurysm exclusion.
- central I ow metal to vessel rati o zone 120 has a I ow metal to vessel ratio.
- the metal to vessel ratio of central low metal to vessel ratio zone 120 is less than 30%.
- the metal to vessel ratio of central low metal to vessel ratio zone 120 is sufficientl low to allow perfusion of branch vessels through central low metal to vessel ratio zone 120.
- variable zone high metal to vessel ratio stent 100 isformed of balloon expandable and/or self-expandi g metal , e.g., e.g., formed of Niti no! or stai nl ess steal .
- vari abl e zone high metal to vessel ratio stent 100 is integral , i .e., a single piece and not a plural ity of separate pieces connected together.
- a cyl indrical tube of metal e.g., Nitino!
- vari abl e zone high metal to vessel rati o stent 100 The cylindrical tube of metal can be formed from a metal sheet that is bent and welded in one embodi ment. As illustrated in FIG. 2, vari able zone high metal to vessel ratio steit 100 has a thickness!, e.g., equal to the thickness of the cyl indrical tube from which vari able zone high metal to vessel ratio stent 100 is formed.
- Variablezone high metal to vessel ratio stent 100 includes a plural ity of serpentine rings 124, 126, 128, sometimes called first, second, aid third serpentine ri gs 124, 126, 128, connected together by connector bars 130.
- each serpentine ring 124, 126, 128 includes a repeating pattern of proximal apexes 132 aid distal apexes 134 connected by struts 136.
- Proxi mal apexes 132 and di sta! apexes 134 are someti mes cal I ed peaks and val I eys, respective! y, or crowns.
- proximal high metal to vessel ratio zone 118 is formed of serpentine ri gs 124 connected together by connector ba"s 130.
- Central low metal to vessd ratio zone 120 is formed of serpentine rings 128 connected together by connector ba * s 130.
- Distal high metal to vessel ratio zone 122 is formed of serpentine ri gs 128 connected together by connector bars 130.
- serpenti ne ri ngs 126 are I arger thai serpent i ne ri ngs 124, 128.
- each serpenti ne ri ng 124, 126, 128 has a wavd ength and an ampl itude.
- the ampl itude is defined as the peak deviation of the serpentine ring from its center position in longitudinal direction 112.
- Serpenti ne ri ngs 124 of proxi mal high metal to vessd rati o zone 118 have a first wavelength ⁇ ! and a first ampl itude A1.
- Serpentine rings 126 of centra] I ow metal to vessd rati o zone 120 have a second wavd ength KZ aid a second ampl itude A2.
- Serpentine rings 128 of distal high metal to vessd ratio zone 122 have a third wavelength )Q and a third ampl itude A3.
- Wavd ength ⁇ 2 aid ampl i tude A2 of serpenti ne ri rigs 126 of central low metal to vessd ratio zone 120 are larger than wavd ength A1 and amp! itude A 1 of serpenti ne ri ngs 124 of proxi mal high metal to vessd ratio zone 118.
- wavd ength K2 aid ampl i tude A2 of serpentine ri ngs 126 of central I ow metal to vessd rati o zone 120 are al so I arga" than wavdength ⁇ and ampl itude A3 of serpentine rings 128 of distal high metal to vessd ratio zone 122.
- FIG. 3 is a cross-sectional view of avessd assembly 300 including a dd ivay system 302 including variable zone high metal to vessd ratio stent 100 of FIGS. 1 and 2 in accordance with one embodiment.
- FIG. 4 is a cross-sectional view of vessd assembly 300 including del ivery system 302 at a lata stage of deploying variable zone high metal to vessd ratio stent 100 of FIGS. 1 and 2 in accordance with one embodi ment.
- a mai vessd 304 e.g., the aorta, includes an aneurysm 306.
- Variable zone high metal to vessd ratio stent 100 someti mes cal I ed a prosthesi s, i s depl oyed i nto mai n vessd 304 to excl ude aneurysm 306 using dd ivery system 302.
- Emanating from main vessd 304 is afirst branch vessd 308 and a second branch vessd 310, someti mes cal led visceral branches of the abdominal aorta
- the location of branch vessds 308, 310 vary from patient to patient.
- branch vessds 308, 310 ind ude the renal arteries (RA), the superior mesenteric artery (SMA), the bracbiocephal ic artery, the left subclavian artery, the left common carotid, the cel iac trunk, aid the hypogastric artery.
- RA renal arteries
- SMA superior mesenteric artery
- bracbiocephal ic artery the left subclavian artery
- the left common carotid the cel iac trunk
- aid the hypogastric artery aid the hypogastric artery.
- Del ivery system 302 is advanced to the location of aneurysm 306, e.g., over aguidewire312, for example as illustrated in FIG. 3.
- Del ivery system 302 includes a tapered tip 314 that is flexible and able to provide trackabi I ity in tight and tortuous vessels.
- Tapered tip 314 includes a lumen 316 allowing for passageof guidewire312 in accordance with this embodiment.
- del ivery system 302 includes radiopaque mar ker(s) that allow visual ization of del i ery system 302.
- variable zone high metal to vessel ratio stent 100 To deploy variable zone high metal to vessel ratio stent 100, an i nner member 318 of del ivery system 302 i nd udi ng tapered ti p 314 mounted thereon is held stationary whiiean outer sheath 320 of del ivery system 302 is withdrawn, for example, as illustrated in FIG. 4. Variablezone high metal to vessel ratio stent 100 is radially constrained by outer sheath 320 around inner member 318. I nner member 318 i ncl udes a stent stop or other features to prevent variablezone high metal to vessel ratio stent 100 from moving back as outer sheath 320 is withdrawn.
- variablezone high metal to vessel ratio stent 100 is gradually exposed from proximal end 10OP to distal end 100D of variablezone high metal to vessel ratio stent 100.
- the exposed portion of variable zone high metal to vessel rati o stent 100 radi al i y expands to be I n conform! ng surf ace contact with mai vessel 304.
- variablezone high metal to vessel rati o stent 100 opposes the wal I s of mai n vessel 304 thus securi ng vari abi e zone high metal to vessel ratio stent 100 in place.
- variablezone high metal to vessel ratio stent 100 is self -expanding and thus self expands upon being released from outer sheath 320.
- vari able zone high metal to vessel ratio stent 100 i s expanded with a bal I con or other expansion devi ce.
- FIG. 5 is a cross-sectional view of vessel assembly 300 of FIGS. 3 and 4 after deployment of vari able zone high meta! to vessel ratio stent 100 of FIGS. 1 and 2 in accordance with one embodiment.
- variablezone high metal to vessel ratio stent 100 is in conforming surf ace contact with main vessd 304.
- Variable zone high metal to vessel ratio stent 100 is deployed such that variable zone high metal to vessel ratio stent 1 0 covers, someti mes call ed j ai I s, ostai (pi ura! of osti um) 322, 324 of branch vessel s 308, 310, respectively.
- proximal high metal to vessel ratio zone 118 is deployed with fixation and seal ing to main vessel 304 superior to branch vessels 308, 310 and anajrysm 308, e.g., to healthy tissue of mai vessel 304 proximal to branch vessels 308, 310. This minimizes the risk of migration of variable zone high metal to vessel ratio stent 100. Further, this a!
- variable zone high metal to vessd ratio stent 100 to heal thy tissue even whan aneurysm 306 has a short neck, i .a, when the distance between aneurysm 306 and branch vessd s 308, 310 i s rel ati vel y smal I , as we! I as when aneurysm 306 has a highly angulated neck.
- variable zone high metal to vessd ratio stent 100 deployment of variable zone high metal to vessd ratio stent 100 is rdati dy simple thus minimizing the complexity and thus risk of deploying variable zone high metal to vessel ratio stent 100. More particularly, as the enti re central low metal to vessd ratio zone 120 is permeable, variable zone high metal to vessd ratio stent 100 isdep!oyed without having to rotationaliy position variable zone high metal to vessd ratio stent 100 to be al igned with branch vessd s 308, 310.
- variable zone high metal to vessd ratio stent 100 includes seal I ops, i .e., cutouts or openings. These seal lops are al igned with ostai 322, 324 of branch vessd s 308, 310.
- seal I ops i .e., cutouts or openings.
- distal high metal to vessd ratio zone 122 covers and exd udes aneurysm 306. M ore parti cul arl y , once vari abi e zone high metal to vessd ratio stent 100 is anchored within main vessd 304, blood flows through mai I umen 106 thus exci udi ng aneurysm 306.
- distal high metal to vessel ratio zone 122 is deployed with fixation aid seal ing to main vessel 304 inferior to aneurysm 306, e.g., to healthy tissue of main vessel 304. This further facil itates excl usion of aneurysm 306 while at the same time minimizes the risk of migration of variable zone high metal to vessel ratio stent 100.
- variable zone high metal to vessel ratio stent 100 is a bifurcated stent, e.g., variable zone high metal to vessel ratio stent 100 is bifurcated to extend into the ⁇ sac arteries.
- branch vessels 308, 310 are adequately perfused through variable zone high metal to vessel ratio stent 100.
- proximal and distal high metal to vessel ratio zones 118, 122 to have a high metal to vessel ratio, tissue ingrowth of main vessel 304 i to variable zone high metal to vessel ratio stent 100 is encouraged.
- vari abl e zone high metal to vessel ratio stent 100 is integral , i .e., is a single piece and not a pl ural ity of separate pieces connected together. More particularly, proximal high metal to vessel ratio zone 118, centra! low metal to vessel ratio zone 120, and distal high metal to vessel ratio zone 122 are al l integral parts of vari able zone high metal to vessel ratio stent 100.
- vari able zone high metal to vessel ratio stent 100 is laser cut from a tube.
- vari able zone high metal to vessel ratio stent 100 is integral , vari able zone high metal to vessel ratio stent 100 is deployed in a single operation which reduces procedure time and complexity. This is in stark contrast to depl oy ing mulfi pie stents one within another to vary the metal to vessel ratio of the resulti g muiti stent arrangement.
- FI G. 6 is a cross-sectional vi ew of vessel assembl y 300 of Fl G. 5 il l ustrating tissue 602 ingrowth into vari able zone high metal to vessel ratio stent 100.
- F! G. 6 111 ustrates i ngrowf h of ti ssue 602 after a peri od of ti me, e.g., weeks or months, after the deployment of vari able zone high metal to vessel ratio stent 100 into main vessel 304.
- ti ssue 602 of main vessel 304 grows through holes 110 of proximal high metal to vessel ratio zone 118 of vari able zone high metal to vessel ratio stent 100.
- Tissue 602 encases, sometimes cal led encloses or encapsulates, material 108 of proximal high metal to vessel ratio zone 118 of variable zone high metal to vessel ratio stent 100.
- proximal high metal to vessel ratio zone 118 is sometimes referred to as a proximal fixation region.
- ti ssue 602 of mai n vessel 304 grows through hoi es 110 of distal high metal to essd rati o zone 122 of variable zone high metal to vessel ratio stent 100.
- Ti ssue 602 encases, someti mes cal I ed end oses or encapasi ates, rnateri al 108 of distal high metal to vessel rati o zone 122 of variable zone high metal to vessel ratio stent 100.
- distal high metal to vessd ratio zone 122 is someti mes referred to as adistai fixation region.
- vari abi e zone high metal to vessd ratio stent 100 includes a surface treatment, e.g., on proximal and distal high metal to essd ratio zones 118, 122.
- a thin layer of metal is appl ied, e.g., by sputtering, physical vapor deposit! on (FVD), plasma enhanced chemical vapor deposition (PECVD), or other appl ication technique, to vari able zone high metal to vessd ratio stent 100 to encourage tissue ingrowth.
- suitable metals include gold, stain! ess steel , titanium oxide, and/or copper, or combinations thereof are appl ied to vari able zone high metal to vessd ratio stent 100 to encourage tissue ingrowth.
- the sur ace treatment i ncl udes rougheni ng the surface of van able zone high metal to vessd ratio stent 100 to encourage tissue i ngrowth.
- the surf ace can be roughened by plasma etching, laser etching, sandblasti g, a sdective etch to preferentially etch one component of vari abl e zone h gh metal to vessel rati o stent 100 over" another, or other surface rougheni g technique.
- the surf ace treatment i nci udes a growth factor appi ied to vari able zone high metal to vessel ratio stent 100 to enhance tissue i ngrowth i nto vari abi e zone high metal to vessel rati o stent 100.
- Exampl es of growth factors include vascular endothel ial growth factor (VEGF), platelet-derived growth factor (PDGF), plated-derived epidermal growth factor (PDEGF), fibroblast growth factors (FGFs), basic fibroblast growth factor (bFGF), transforming growth factor-beta (TGF-.beta), piatdet-deri ed angiogenesis growth factor (PDAF) and autologous platelet gel (APG).
- VEGF vascular endothel ial growth factor
- PDGF platelet-derived growth factor
- PEGF plated-derived epidermal growth factor
- FGFs fibroblast growth factors
- bFGF basic fibroblast growth factor
- TGF-.beta transforming growth factor-beta
- PDAF piatdet-deri ed angiogenesis growth factor
- APG autologous platelet gel
- growth factors include bioactive materials, e.g., a bioactive compound . , drug, therapeutic agent or composition having a biological effect in an animal .
- Bioactive materials indudesmall molecules, peptides, proteins, hormones, DNA or RNA fragments, genes, cells, genetically-modified eel is, cell growth promoting compositions, inhibitors of matrix metal ioprotei ase, fatty aci ds and autoi ogous pi atd et gel .
- FIG. 7 is a cross-sectional view of a vessel assembly 300A including a vari able zone high metal to vessel ratio stent graft 700 in accordance with another embodiment.
- Vessel assembly 300A includes main vessel 304, anairysm 306, branch vessels 308, 310, ostai 322, 324 as discussed above in reference to FIGS. 3-8.
- vessel assembly 300A includes first and second bifurcated vessels726, 728, e.g., the iliac arteries.
- Vessel assembly 300A also include a bifurcated branch vessd 730, e.g., the hypogastric artery, sorneti mes cal I ed f he I nfernal i I i ac artery, branch! ng from f i rst bifurcated vessel 726.
- Vari abl e zone high metal to vessd rati o stent graft 700 i ncl udes a vari able zone high metal to vessel ratio stent 100A, a bifurcated graft material 734, aid stents 736, 738.
- Variable zone high metal to vessd ratio stent 100A includes a proximal high metal to vessd ratio zone 118, a central low metal to vessd ratio zone 120, and a distal high metal to vessd ratio zone 122.
- variable zone high metal to vessd ratio stent 100A is formed of a wire weave. More particularly, proximal high metal to vessd ratio zone 118 is formed of a dense wire weave with fixation and seal ing to main vessd 304 superior to aneurysm 306.
- the wire weave is longitudinally expanded in longitudinal direction 112 over branch vessels 308, 310 to form central low metal to vessd ratio zone 120 of a spare wi re weave.
- central I ow metal to vessel rati o zone 120 is highly permeable, blood flows from main vessel 304 through central low metal to vessd ratio zone 120 and i nto branch vessd s 308, 310 thus perfusi g branch vessd s 308, 310.
- Distal high metal to vessd rati o zone 122 is a! so formed of a dense wire weave. Distal high metal to vessd ratio zone 122 is attached, e.g., to the outside, of a proximal region 740 of bifurcated graft material 734. Accordingly, di stal hi gh metal to vessd rati o zone 122 ai I ows for ti ssue i ntegrati on and thus seal mhancement of bifurcated graft material 734 to main vessd 304.
- Bifurcated graft maferi ai 734 covers and excl udes aneurysm 306. Further, bifurcated graft material 734 includes first and second legs 742, 744, sometimes called bifurcations, that extend into first and second bifurcated vessd s 726, 728. Optionally, oneor more support structures 746, e.g., sinusoidal stent rings, are attached to bifurcated graft materia! 734 to enhance expansion of bifurcated graft material 734. Although one particular example of bifurcated graft material 734 and support structures 746 is illustrated aid discussed, in l ight of this disclosure, those of skill in the art will understand that other graft designs are used in other embodiments.
- support structures 746 e.g., sinusoidal stent rings
- Fi rst and second stents 736, 738 are attached to I egs 742, 744, respectivdy, of bifurcated graft material 734 to enhancedistal fixation of legs 742, 744, to first and second bifurcated vessds 726, 728.
- stents 736, 738 are formed of a wire weave.
- stent 736 extends over an osti urn 748 of bi furcated branch vessd 730. Blood flows from first bifurcated vessd 726 through stent 736 and into bifurcated branch vessd 730 thus perfusing bifurcated branch vessd 730.
- FIG. 8 is a cross-sectional view of a vessel assembly 3G0B including a variable zone high metal to vessd ratio stent graft 800 in accordance with yet another embodiment.
- Vessd assembly 300B includes main vessd 304, aneurysm 306, branch vessd s 308, 310, ostai 322, 324, first and second bifurcated vessd s 726, 728, bifurcated branch vessd 730 includi g ostium 748, as discussed above in reference to FIG. 7.
- Variable zone high metal to vessel ratio stent graft 800 includes a variable zone high metal to vessel ratio stent 100B, bifurcated graft material 734, and stents 736B, 738B.
- Variab!ezone high metal to vessel ratio stent 10QB is simiiar to variable zone high metal to vessel ratio stent 100A as discussed above in reference to FIG. 7 and only the significant differences are discussed below.
- Variablezone high metal to vessel ratio stent 100B i cludes a proximal high metal to vessel ratio zone 118, a central low metal to vessel ratio zone 120, and a distal high metal to vessel ratio zone 122.
- variable zone high metal to vessel ratio stent 100B is formed of a laser cut structure and/or a wire formed and crimped structure.
- Proximal high metal to vessel ratio zone 118 e.g., a high metal to vessel ratio mesh, has fixation and seal ing to main vessel 304 superior to branch vessels 308, 310 and aneurysm 308.
- Distal high metal to vessel ratio zone 122 is also a high metal to vessel ratio mesh. Distal high metal to vessel ratio zone 122 is attached, e.g., to the outside, of proximal region 740 of bifurcated graft material 734. Accordingly, di stal hi gh metal to vessel rati o zone 122 ai I ows for ti ssue i ntegrati on and thus seal enhancement of bifurcated graft material 734 to main vessel 304.
- Bifurcated graft material 734 covers and excl udes aneurysm 306.
- Stents 738B, 738B are attached to I egs 742, 744, respectively, of bifurcated graft material 734 to enhance distal fixation of I egs 742, 744 to f i rst and second bifurcated vessel s 728, 728.
- stents 736B, 738B are formed of a high metal to vessel ratio mesh to promote seal i ng of I egs 742, 744 to f i rst and second bifurcated vessels 726, 728.
- stent 736B is proximal to ostium 748 of bifurcated branch vessel 730. Accordingly, blood flows unrestricted from first bifurcated vessel 726 into bifurcated branch vessel 730 thus perfusing bifurcated branch vessel 730.
- Thisdisd osure provi des exempl ary embodi merits.
- the scope i s not l imited by these exempl ary embodiments.
- Numerous variations, whether expl icitly provided for by the specifi cation or implied by the specification or not, such as variations in structure, dimension, type of material and manufacturing process may be i mpi emented by one of ski 11 i n the art i n vi ew of thi s di sd osure.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Prostheses (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/430,907 US9393136B2 (en) | 2012-03-27 | 2012-03-27 | Variable zone high metal to vessel ratio stent and method |
| PCT/US2013/026546 WO2013148011A1 (en) | 2012-03-27 | 2013-02-16 | Variable zone high metal to vessel ratio stent and method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2830546A1 true EP2830546A1 (en) | 2015-02-04 |
| EP2830546B1 EP2830546B1 (en) | 2019-10-30 |
Family
ID=47843408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP13708291.3A Active EP2830546B1 (en) | 2012-03-27 | 2013-02-16 | Variable zone high metal to vessel ratio stent and method |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US9393136B2 (en) |
| EP (1) | EP2830546B1 (en) |
| WO (1) | WO2013148011A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732114B (en) * | 2008-11-04 | 2014-07-30 | 上海微创医疗器械(集团)有限公司 | Coronary artery stent with medicine carrying grooves |
| EP3656354B1 (en) | 2011-12-06 | 2021-02-03 | Aortic Innovations LLC | Device for endovascular aortic repair |
| US9107770B2 (en) * | 2012-02-14 | 2015-08-18 | W. L. Gore & Associates, Inc. | Endoprosthesis with varying compressibility and methods of use |
| US8911490B2 (en) * | 2012-03-27 | 2014-12-16 | Medtronic Vascular, Inc. | Integrated mesh high metal to vessel ratio stent and method |
| US9005270B2 (en) | 2012-03-27 | 2015-04-14 | Medtronic Vascular, Inc. | High metal to vessel ratio stent and method |
| US20160081823A1 (en) * | 2014-09-23 | 2016-03-24 | Cordis Corporation | Endoprosthesis with predetermined curvature formed by tri-tethers |
| US11065019B1 (en) | 2015-02-04 | 2021-07-20 | Route 92 Medical, Inc. | Aspiration catheter systems and methods of use |
| US10716915B2 (en) | 2015-11-23 | 2020-07-21 | Mivi Neuroscience, Inc. | Catheter systems for applying effective suction in remote vessels and thrombectomy procedures facilitated by catheter systems |
| ES3041086T3 (en) | 2016-06-13 | 2025-11-06 | Bolton Medical Inc | Devices for reinforcing fenestrations in prosthetic implants |
| WO2019060816A2 (en) | 2017-09-25 | 2019-03-28 | Aortica Corporation | Systems, devices, and methods for coupling a prosthetic implant to a fenestrated body |
| ES3041117T3 (en) * | 2019-02-01 | 2025-11-07 | Bolton Medical Inc | Expandable luminal stents |
| EP3941392B1 (en) | 2019-03-20 | 2025-04-23 | Inqb8 Medical Technologies, LLC | Aortic dissection implant |
| DE102019112971A1 (en) * | 2019-05-16 | 2020-11-19 | Optimed Medizinische Instrumente Gmbh | STENT |
| EP4225167A4 (en) | 2020-10-09 | 2024-10-09 | Route 92 Medical, Inc. | Aspiration catheter systems and methods of use |
| US20250221834A1 (en) * | 2024-01-09 | 2025-07-10 | Route 92 Medical, Inc. | Systems and methods for treating vascular disease |
| CN120585532B (en) * | 2025-08-07 | 2025-11-14 | 北京久事神康医疗科技有限公司 | An intravascular stent |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5609627A (en) * | 1994-02-09 | 1997-03-11 | Boston Scientific Technology, Inc. | Method for delivering a bifurcated endoluminal prosthesis |
| US6051020A (en) * | 1994-02-09 | 2000-04-18 | Boston Scientific Technology, Inc. | Bifurcated endoluminal prosthesis |
| US5817152A (en) | 1994-10-19 | 1998-10-06 | Birdsall; Matthew | Connected stent apparatus |
| US6190402B1 (en) | 1996-06-21 | 2001-02-20 | Musc Foundation For Research Development | Insitu formable and self-forming intravascular flow modifier (IFM) and IFM assembly for deployment of same |
| US7341598B2 (en) * | 1999-01-13 | 2008-03-11 | Boston Scientific Scimed, Inc. | Stent with protruding branch portion for bifurcated vessels |
| US5817126A (en) | 1997-03-17 | 1998-10-06 | Surface Genesis, Inc. | Compound stent |
| US6258115B1 (en) | 1997-04-23 | 2001-07-10 | Artemis Medical, Inc. | Bifurcated stent and distal protection system |
| US6093199A (en) | 1998-08-05 | 2000-07-25 | Endovascular Technologies, Inc. | Intra-luminal device for treatment of body cavities and lumens and method of use |
| US6273910B1 (en) * | 1999-03-11 | 2001-08-14 | Advanced Cardiovascular Systems, Inc. | Stent with varying strut geometry |
| US6287335B1 (en) | 1999-04-26 | 2001-09-11 | William J. Drasler | Intravascular folded tubular endoprosthesis |
| US20020013616A1 (en) * | 2000-05-05 | 2002-01-31 | Andrew Carter | Multilayer stents having enhanced flexibility and hoop strength |
| BE1013757A6 (en) | 2000-12-12 | 2002-07-02 | Frid Noureddine | Luminal endoprosthesis MODULAR. |
| US20030100945A1 (en) | 2001-11-23 | 2003-05-29 | Mindguard Ltd. | Implantable intraluminal device and method of using same in treating aneurysms |
| CA2452953A1 (en) | 2001-07-18 | 2003-01-30 | The Research Foundation Of State University Of New York | Stent vascular intervention device and method |
| US20030176914A1 (en) * | 2003-01-21 | 2003-09-18 | Rabkin Dmitry J. | Multi-segment modular stent and methods for manufacturing stents |
| US7163553B2 (en) * | 2001-12-28 | 2007-01-16 | Advanced Cardiovascular Systems, Inc. | Intravascular stent and method of use |
| US20030204244A1 (en) * | 2002-04-26 | 2003-10-30 | Stiger Mark L. | Aneurysm exclusion stent |
| US7331987B1 (en) * | 2002-08-16 | 2008-02-19 | Advanced Cardiovascular Systems, Inc. | Intravascular stent and method of use |
| US7112216B2 (en) * | 2003-05-28 | 2006-09-26 | Boston Scientific Scimed, Inc. | Stent with tapered flexibility |
| US7093527B2 (en) | 2003-06-10 | 2006-08-22 | Surpass Medical Ltd. | Method and apparatus for making intraluminal implants and construction particularly useful in such method and apparatus |
| US7275471B2 (en) | 2003-12-29 | 2007-10-02 | Surpass Medical Ltd. | Mixed wire braided device with structural integrity |
| US7069835B2 (en) | 2004-01-12 | 2006-07-04 | Surpass Medical Ltd. | Striped braided element |
| US8617234B2 (en) * | 2004-05-25 | 2013-12-31 | Covidien Lp | Flexible vascular occluding device |
| US7744641B2 (en) * | 2004-07-21 | 2010-06-29 | Boston Scientific Scimed, Inc. | Expandable framework with overlapping connectors |
| US8900287B2 (en) | 2006-01-13 | 2014-12-02 | Aga Medical Corporation | Intravascular deliverable stent for reinforcement of abdominal aortic aneurysm |
| WO2008051554A2 (en) | 2006-10-24 | 2008-05-02 | Beth Israel Deaconess Medical Center | Percutaneous aortic valve assembly |
| EP2111190B1 (en) | 2007-01-19 | 2013-10-09 | Medtronic, Inc. | Stented heart valve devices for atrioventricular valve replacement |
| US8430927B2 (en) | 2008-04-08 | 2013-04-30 | Medtronic, Inc. | Multiple orifice implantable heart valve and methods of implantation |
| WO2010024868A1 (en) * | 2008-08-27 | 2010-03-04 | Cook Incorporated | Multi-section stent |
| US8419782B2 (en) * | 2009-04-09 | 2013-04-16 | Medtronic Vascular, Inc. | Precise positioning prosthesis delivery system and method |
| US20110137407A1 (en) * | 2009-07-09 | 2011-06-09 | Thai Minh Nguyen | Bare metal stent with drug eluting reservoirs |
| US20120022578A1 (en) * | 2010-07-20 | 2012-01-26 | Cook Medical Technologies Llc | Frame-based vena cava filter |
-
2012
- 2012-03-27 US US13/430,907 patent/US9393136B2/en active Active
-
2013
- 2013-02-16 WO PCT/US2013/026546 patent/WO2013148011A1/en not_active Ceased
- 2013-02-16 EP EP13708291.3A patent/EP2830546B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9393136B2 (en) | 2016-07-19 |
| US20130261727A1 (en) | 2013-10-03 |
| EP2830546B1 (en) | 2019-10-30 |
| WO2013148011A1 (en) | 2013-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2830546A1 (en) | Variable zone high metal to vessel ratio stent and method | |
| US8911490B2 (en) | Integrated mesh high metal to vessel ratio stent and method | |
| US9005270B2 (en) | High metal to vessel ratio stent and method | |
| JP5567010B2 (en) | Biodegradable prosthesis | |
| US7025779B2 (en) | Endoluminal device having enhanced affixation characteristics | |
| CA2370184C (en) | Multi-section stent | |
| EP1047357A1 (en) | Stent having non-uniform structure | |
| US20100292777A1 (en) | Stent | |
| US20080275543A1 (en) | Stent | |
| JP2004160236A (en) | Endoprosthesis | |
| JP2011507604A (en) | Stent | |
| WO1998051238A1 (en) | Expandable stent and method for production of same | |
| US10744011B2 (en) | Monolithic medical devices and methods of use | |
| KR20130138189A (en) | Flexible stent having protruding hinges | |
| JP2008237880A (en) | Intraluminal medical device having variable axial flexibility about circumference of the device | |
| EP2088963B1 (en) | Bifurcation stent design with over expansion capability | |
| US20120271399A1 (en) | High Metal to Vessel Ratio Landing Zone Stent-Graft and Method | |
| KR101676265B1 (en) | Flexible helical stent having intermediate structural feature | |
| US20090018641A1 (en) | Large vessel stents | |
| EP1100409B1 (en) | Small vessel expandable stent | |
| JP2016510657A (en) | Topographic features and patterns on the surface of medical devices and methods of making the same | |
| EP1928351A2 (en) | Vascular prosthesis having interdigitating edges and methods of use | |
| WO2014013444A2 (en) | Endoluminal vascular prostheses for small vessels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20141013 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20160908 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602013062211 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61F0002915000 Ipc: A61F0002900000 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61F 2/90 20130101AFI20190320BHEP Ipc: A61F 2/848 20130101ALI20190320BHEP Ipc: A61F 2/915 20130101ALI20190320BHEP Ipc: A61F 2/07 20130101ALI20190320BHEP Ipc: A61F 2/91 20130101ALI20190320BHEP Ipc: A61F 2/06 20130101ALI20190320BHEP |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20190527 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1195360 Country of ref document: AT Kind code of ref document: T Effective date: 20191115 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602013062211 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200130 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200131 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200130 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200302 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20191030 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200229 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602013062211 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1195360 Country of ref document: AT Kind code of ref document: T Effective date: 20191030 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| 26N | No opposition filed |
Effective date: 20200731 |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20200216 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20200229 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200216 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200229 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200229 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200216 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200229 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191030 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20250122 Year of fee payment: 13 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20250124 Year of fee payment: 13 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20250121 Year of fee payment: 13 |